Selective dopamine D3 receptor partial agonist (±)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement
- PMID: 39527868
- PMCID: PMC11588530
- DOI: 10.1016/j.drugalcdep.2024.112494
Selective dopamine D3 receptor partial agonist (±)VK4-40 reduces the reinforcing strength of d-amphetamine but not cocaine in rhesus monkeys responding under a progressive-ratio schedule of reinforcement
Abstract
Background: Although countless studies have aimed to identify and test novel therapeutics for stimulant misuse, there are still no FDA-approved pharmacotherapies for stimulant use disorders. One potential treatment target is the dopamine D3 receptor (D3R) and studies in rodents have suggested that the novel D3R partial agonist (±)VK4-40 may be effective at decreasing cocaine self-administration. However, no previous studies have examined the efficacy of (±)VK4-40 in reducing cocaine self-administration in nonhuman primates nor the generality of effects by examining self-administration of other stimulants using a within-subjects design.
Methods: Experiment 1 examined how acute treatment with (±)VK4-40 (1.7-3.0mg/kg, i.v.) influenced cocaine and d-amphetamine self-administration in three rhesus monkeys responding under a progressive-ratio (PR) schedule of reinforcement. In Experiment 2, the reinforcing effects of (±)VK4-40 were evaluated under a PR schedule and compared to cocaine and d-amphetamine.
Results: When given as a pretreatment, (±)VK4-40 significantly reduced the reinforcing strength of d-amphetamine but not cocaine. In general, the effects of (±)VK4-40 on d-amphetamine responding were parallel downward shifts in the self-administration dose-response curve. When (±)VK4-40 was substituted for cocaine, it functioned as a reinforcer in 2 of 3 monkeys. However, the reinforcing strength of (±)VK4-40 was significantly lower than cocaine and d-amphetamine, suggesting lower potential for misuse.
Conclusions: Overall, these findings support further exploration of D3R partial agonists, including (±)VK4-40, for treatment of d-amphetamine misuse or potentially in combination with d-amphetamine for treatment of cocaine use disorder.
Keywords: Cocaine; Monkey; Pharmacotherapies; Self-administration; d-amphetamine.
Copyright © 2024. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest None.
References
-
- Mattiuzzi C and Lippi G, Worldwide epidemiology of alcohol and drugs abuse. European journal of internal medicine, 2019. 70: p. e27–e28. - PubMed
-
- Knopf A, 2022 NSDUH finds most people with SUD don’t seek treatment. Alcoholism & Drug Abuse Weekly, 2023. 35(45): p. 3–5.
-
- Manthey J, et al., Estimating the economic consequences of substance use and substance use disorders. Expert Review of Pharmacoeconomics & Outcomes Research, 2021. 21(5): p. 869–876. - PubMed
-
- Hedegaard H, et al., Drug overdose deaths in the United States, 1999–2020. 2021. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials